Under the three-year collaboration, Empirico will use its Precision Insights Platform to determine therapeutic targets for indications and tissues, which are responsive to antisense technology. The Precision Insights
The technology is expected to be capable of enumerating, screening, and scoring billions of synthetically feasible, virtual compounds supporting the identification and optimization of potential new therapeutic candidates.
Keytruda has been approved to treat patients with BCG- unresponsive, high-risk NMIBC with carcinoma in situ (CIS) with or without papillary tumours who are ineligible for or have
The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “The EMA’s validation of Incyte’s Marketing
Reported to be the world’s largest independent funder of cancer research, Cancer Research UK will provide funding for the exploratory development of Bicycle’s BT7401 candidate through a phase
TCTC Group provides clinical operations, regulatory, personnel and medical services for full-service clinical studies and stand-alone clinical trials for biopharmaceutical companies throughout the world. The acquisition of TCTC
Under an exclusive worldwide research collaboration and licence agreement, the companies will be engaged in the development of small molecule inhibitors against several drug targets, which include the
Dysport, an injectable form of a botulinum neurotoxin type A product, is a substance derived from Clostridium bacteria producing botulinum toxin type A (BoNT-A), which blocks the effective
As part of the collaboration and licence agreement, the companies will work together to detect small molecules designed to modulate specific pathways linked with a targeted indication within
The US regulator has approved Lynparza as a maintenance treatment for adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) whose disease
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.